Orfonyx Bio
Developing a new class of genetic medicines for protein upregulation
What we do
An emerging class of genetic medicines
Here at Orfonyx Bio, we are harnessing our unique insights and proprietary computational platform to develop an emerging class of genetic medicines that target regulatory elements in untranslated regions of genes. By exploiting our APEX (Activation of Protein Expression) antisense oligonucleotide technologies, we can specifically inhibit repressive sequence motifs to enhance protein expression of target genes to address diseases with an unmet need.
Who we are
Building on expertise and knowledge
Founded in 2022, Orfonyx Bio is a seed-stage company spun out of the University of Oxford and funded by Oxford Sciences Enterprises. With both academic and industry experience, our small but dedicated and passionate team, are building on the expertise and knowledge developed by our co-founders in the group of Professor Matthew Wood.
Contact
Please use the form below to get in touch with us!